APSR2026-1095

 
Big-5
Submitted
Big-5
 
BIG5-04
 
 
Format: PPTX Only
 
Format: PDF Only
 
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Muneswarao Jaya * Department of Pharmacy Hospital Pulau Pinang, George Town Penang Malaysia
Pereirasamy Lalitha - Department of Respiratory Medicine Hospital Pulau Pinang, George Town Penang Malaysia
Hyder Ali Irfhan Ali - Department of Respiratory Medicine Hospital Pulau Pinang, George Town Penang Malaysia
Muthukumaru Umadevi A. - Department of Respiratory Medicine Hospital Pulau Pinang, George Town Penang Malaysia
Arumugam Minalosani - Department of Respiratory Medicine Hospital Pulau Pinang, George Town Penang Malaysia
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Muneswarao
Jaya
 
 
 
 
 
The Penang MoDel (PMD)
Maximum 25 words
Abstract Content
The PMD enables direct referrals from primary care (via the Severe Asthma Network Penang) and secondary/tertiary care to the Respiratory Department, Hospital Pulau Pinang. A predefined biologics checklist is used prior to referral. A key component is a multidisciplinary team (MDT) discussion. Approved patients receive pre-biologics counselling and initiation, followed by a second MDT to review response. Patients not approved for biologics are managed under a closely monitored Patient-Centred Care (PCC) approach focusing on treatable traits.
A two-year retrospective cohort study was conducted (2022–2023). All patients managed under PMD were included.
Thirty-one patients underwent PMD; 7 (23%) received biologics, while 24 (77%) were managed under PCC. The biologics group showed significant improvements in ACT (r=0.54), exacerbations (r=0.55), and OCS reduction (r=0.53) (all p<0.05). The PCC group (non-biologics) also improved in ACT (r=0.62), exacerbations (r=0.53) (p<0.001), inhaler technique errors (χ²=1.17; p<0.05), and medication adherence (χ²=5.21; p<0.01). Additionally, the primary care subgroup analysis delineated that the PMD reduced referral-to-appointment time to 3–5 days (vs 14 days pre-PMD), time to diagnosis to 90 days (vs 6 months pre-PMD), and led to treatment modification in 50% of patients. The model was also cost-effective (ICER of RM3,199.82 per severe exacerbation avoided).
PMD improves outcomes and optimises biologic use in severe asthma. Direct primary care referral within PMD enhances timely access and quality of care.
 
 
 
 
 
 
 
 
JPG or JPEG or PNG format ONLY
 
maximum 3 keywords and no abbreviations, separated by commas